Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients

por Karaba, Andrew H., Kim, Jake D., Chiang, Teresa P-Y., Alejo, Jennifer L., Sitaras, Ioannis, Abedon, Aura T., Eby, Yolanda, Johnston, Trevor Scott, Li, Maggie, Aytenfisu, Tihitina, Hussey, Casey, Jefferis, Alexa, Fortune, Nicole, Abedon, Rivka, Thomas, Letitia, Habtehyimer, Feben, Ruff, Jessica, Warren, Daniel S., Avery, Robin K., Clarke, William A., Pekosz, Andrew, Massie, Allan B., Tobian, Aaron A.R., Segev, Dorry L., Werbel, William A.
Publicado 2023